

January 05, 2026

To
BSE Limited
P.J. Towers, Dalal Street,
Mumbai – 400 001
Scrip Code: 544647
Through: BSE Listing Centre

To
National Stock Exchange of India Limited
5th Floor, Exchange Plaza, Bandra (E),
Mumbai – 400 051
Scrip Symbol: NEPHROPLUS
Through: NEAPS

Sub: Outcome of the Board Meeting held on January 05, 2026**Ref: Regulation 30 read with Para A of Part A of Schedule III and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Ma'am,

Pursuant to Regulation 30 read with Para A of Part A of Schedule III and other applicable provisions if any of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**SEBI Listing Regulations**”), we hereby inform you of the outcome of the Board meeting held today:

1. The Board of Directors after taking into account the recommendations of Nomination and Remuneration Committee, approved re-appointment of Mr. Om Prakash Manchanda (DIN: 02099404) as an Independent Director of the Company for the second term of three (3) consecutive years commencing from February 11, 2026 up to February 10, 2029, not liable to retire by rotation, subject to approval of the shareholders by way of a special resolution.

We further submit that in accordance with the circulars dated June 20, 2018 issued by the Stock Exchanges, Mr. Om Prakash Manchanda has confirmed that he is not debarred from holding the office of Director by virtue of any order(s) passed by SEBI or any other such authority.

2. The Board of Directors after taking into account the recommendations of the Audit Committee, approved the appointment of M/s Makarand M. Joshi & Co., Company Secretaries in Practice, Mumbai (Firm Registration No.: P2009MH007000; Peer Review No.: 6832/2025), as the Secretarial Auditor of the Company for a tenure of five consecutive financial years commencing from April 1, 2025 up to March 31, 2030 and recommended the same to the Shareholders for approval.



Brief details about the appointment as mentioned above pursuant to Regulation 30 read with Part A of Schedule III of the SEBI Listing Regulations read with Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 are given in **Annexure I**.

The meeting of Board of Directors commenced at 06:00 p.m. IST and concluded at about 06:20 p.m. IST.

Kindly take the same on record.

Yours faithfully,

For Nephrocare Health Services Limited
(Formerly Nephrocare Health Services Private Limited)

Kishore Kathri
Company Secretary and Compliance Officer
Membership No.: F9895

Nephrocare Health Services Limited (Global Corporate Headquarters)

(Formerly Nephrocare Health Services Private Limited)

5th Floor, D Block, iLabs Centre, Plot: 18, Software Units Layout, Survey No: 64, Madhapur, Hyderabad - 500 081, Telangana, India.

+91 40 4240 8039 contactus@nephroplus.com www.nephroplus.com

CIN: U85100TG2009PLC066359 | GSTIN: 36AADCN1504A1Z8

Annexure I

Details in terms of SEBI circular no. SEBI/HO/CFD/POD-2/CIR/P/0155 dated November 11, 2024:

Name of the Director/KMP/SMP/Auditor	Mr. Om Prakash Manchanda, Independent Director (DIN: 02099404)	M/s Makarand M. Joshi & Co., Practising Company Secretaries
Reason for change viz. appointment, reappointment, resignation, removal, death or otherwise	Re-appointed as an Independent Director	Appointment
Date of appointment re-appointment / cessation (as applicable) and term of appointment / reappointment	Re-appointed w.e.f. February 11, 2026 for a period of three (3) consecutive years subject to the approval of shareholders.	Based on the recommendations of the Audit Committee, Board approved the appointment of M/s Makarand M. Joshi & Co., (MMJC), Company Secretaries in Practice, Mumbai (Firm Registration No.: P2009MH007000; Peer Review No.: 6832/2025), as the Secretarial Auditor of the Company for a tenure of five (5) consecutive financial years, commencing from April 1, 2025 up to March 31, 2030. The appointment is subject to the approval of the shareholders of the Company.
Brief profile (in case of appointment)	Om Prakash Manchanda is an Independent Director of our Company. He has been associated with our Company since February 11, 2021. He holds a bachelor's degree in veterinary science and animal husbandry from Haryana Agricultural University, Hisar and a post graduate degree in management (agriculture) from the Indian Institute of Management, Ahmedabad. He has also completed the	Ms. Kumudini Paranjape Bhalerao is a Senior Partner at MMJC and is Fellow Member of Institute of Company Secretary of India (ICSI) and a member of the Auditing Standards Board of ICSI. She has extensive experience working with listed, unlisted, and start-up companies, offering advisory & audit services across various sectors.

	<p>advanced management program from Harvard Business School, United States. He has also earned the CFA Institute Investment Foundations Certificate from the CFA Institute. He started his career in 1990, as a management trainee with Unilever Group of Companies in India (now Hindustan Unilever Limited) where he worked in various capacities including as area manager, innovation manager and business manager. Subsequently, in the year 1999, he joined Monsanto India Limited as national sales manager. Thereafter, in January 2003, he joined Ranbaxy Laboratories Limited. In October 2005, he joined Dr. Lal Path Labs Limited as its chief operating officer and in March 2025, he stepped down as managing director on completion of his term. He was awarded the EY entrepreneur of the year award in 2019 under the field of healthcare and lifesciences. He was also awarded the Healthcare Personality of the Year award in 2020 by FICCI. He has nearly 35 years of work experience in the field of medical science and management.</p>	
<p>Disclosure of relationships between directors (in case of appointment of a director).</p>	<p>NIL</p>	<p>Not Applicable</p>